lesinurad

11/01/2018 - "Although the combination of lesinurad 200 mg and XOI is effective and well tolerated for treating patients with gout who have not achieved an adequate response to XOI monotherapy, clinical gout-related outcomes were not improved. "
01/01/2019 - "Lesinurad, in combination with a XOI, is an effective and safe treatment that covers unmet needs in adults with gout who have not achieved target serum UA levels with a XOI alone."
01/01/2018 - "Lesinurad has a novel mechanism of action and is safe and effective for the treatment of chronic gout. "
01/01/2018 - "To review the pharmacology, efficacy, and safety of lesinurad and determine its role relative to other agents in the management of chronic gout. "
01/01/2018 - "Lesinurad: A Novel Agent for Management of Chronic Gout."

01/10/2021 - "Emergent drugs (lesinurad, peglotidase) were found to be more effective for the acute management of refractory hyperuricemia, but their use is supported by a relatively small number of clinical trials so that further well-designed clinical research is needed to deepen their efficacy and safety profile."
01/01/2021 - "Hepatic and Renal Impacts of Lesinurad on Experimental Hyperuricemia: Biochemical, Molecular and Pathological Investigations."
11/01/2018 - "Efficacy and Safety of Lesinurad in Patients with Hyperuricemia Associated with Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials."
01/01/2019 - "Lesinurad is indicated in adults, in combination with a XOI, for the adjunctive treatment of hyperuricemia in patients with gout (with or without tophi) who have not achieved target serum UA levels with an adequate dose of a XOI alone. "
01/01/2019 - "Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout."

01/01/2021 - "The aim was to evaluate the efficacy, defined as achieving target serum urate <6.0 mg/dl, and safety of urate-lowering therapies (ULTs) for people with gout and chronic kidney disease (CKD) stages 3-5. PubMed, The Cochrane Library and EMBASE were searched from 1 January 1959 to 31 January 2018 for studies that enrolled people with gout, who had an estimated glomerular filtration rate (eGFR) or creatinine clearance (CrCl) of <60 ml/min and exposure to allopurinol, febuxostat, probenecid, benzbromarone, lesinurad or pegloticase. "

03/01/2019 - "Overall, the relative risk for sCri was > 1.0 with the 400 mg/day dose of lesinurad and higher with the 200 mg/day dose, but it was < 1.0 for both lithiasis and renal failure with the 200 mg/day dose. "

03/01/2019 - "Overall, the relative risk for sCri was > 1.0 with the 400 mg/day dose of lesinurad and higher with the 200 mg/day dose, but it was < 1.0 for both lithiasis and renal failure with the 200 mg/day dose. "